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The stem cell field is gradually moving toward translational applications as exemplified by the papers highlighted in this
Stem Cell Select. In vitro human embryonic stem cell (hESC) models of disease may prove useful for drug screening.
Resolving whether cancer stem cells are important for the pathogenesis of all or only some human cancers should accel-
erate development of new stem cell-specific therapeutic strategies. Finally, visualizing how hematopoietic stem cell
grafts colonize bone marrow in real time will provide insights enabling optimization of transplant protocols.
Mutant Astrocytes Stress Out Motor Neurons
The pathogenesis of the neurodegenerative disease amyotrophic lateral sclerosis (ALS) is
complex. However, genetic evidence implicates mutations in the gene encoding superoxide
dismutase (SOD1)—an enzyme that breaks down toxic free radicals—as contributing to the
selective death of motor neurons. Animal models of ALS have shown that once the motor
neurons are damaged and the disease process triggered, then disease progression depends
on nonneuronal cells such as astrocytes, which are thought to be crucial mediators of mutant
SOD1 toxicity. Now, the Gage and Eggan groups (Marchetto et al., 2008; Di Giorgio et al., 2008)
present in vitro models of human ALS comprising motor neurons derived from hESCs
cultured with astrocytes expressing either mutant or wild-type SOD1. Marchetto et al. (2008)
grew hESC-derived motor neurons together with primary human astrocytes expressing either
wild-type or mutant SOD1 (SOD1G37R) and labeled the motor neurons using a lentivirus-
Hb9::GFP construct. In their assay, Di Giorgio and colleagues generated an Hb9::GFP trans-
genic hESC line, which they induced to form motor neurons that were then cocultured with
primary astrocytes derived from either SOD1G93A transgenic or control mice. Both groups
found that when cocultured with astrocytes expressing mutant SOD1 (but not normal
SOD1), the number of motor neurons decreased by50%; coculture with fibroblasts express-
ing mutant SOD1 did not result in motor neuron death. Marchetto et al. then found that a greater number of mutant astrocytes
were activated compared with control astrocytes. Activated astrocytes are part of the inflammatory response, and SOD1G37R
mutant astrocytes were found to boost production of reactive oxygen species (ROS), iNOS, NOX2, and CHGA, a neurosecre-
tory protein that interacts specifically with mutant SOD1. These authors then screened antioxidant compounds in the cocul-
ture system and found that the NOX2 inhibitor apocynin and the antioxidant a-lipoic acid decreased ROS generation. They
further demonstrated that apocynin could abrogate death of motor neurons cocultured with SOD1G37R astrocytes. Di Giorgio
and colleagues performed gene expression profiling to identify genes that are uniquely transcribed in astrocytes overexpress-
ing the SOD1G93A mutation. The authors found increased expression of 53 genes but assayed a subset of genes implicated in
inflammation and immunity for motor neuron survival in the coculture system. Of the agents tested, prostaglandin D2 dramat-
ically decreased motor neuron survival, and blocking the prostaglandin D2 receptor could partly rescue motor neuron loss
caused by astrocytes expressing mutant SOD1. Both studies reveal that the inflammatory component of ALS pathogenesis
can be specifically recapitulated in cultured motor neurons derived from hESCs and that in vitro hESC-based ALS models
may be valuable for screening compounds that specifically affect motor neuron survival.
F.P. Di Giorgio et al. (2008). Cell Stem Cell 3, 637–648.
M.C.N. Marchetto et al. (2008). Cell Stem Cell 3, 649–657.
Cancer Be Gone
Cancer relapse is believed to be caused by a small number of drug-resistant cancer cells that
linger behind after surgery and chemotherapy. According to the cancer stem cell (CSC) hypoth-
esis, these cells are exclusively able to self-renew and can, in phoenix-like fashion, recreate the
original tumor. There is much interest in exploring whether specific targeting of these CSCs
could be exploited to treat cancer. Nasr et al. (2008) now demonstrate that a combination of
retinoic acid (RA) and arsenic trioxide targets leukemia initiating cells (LICs), which are the
root cause of acute promyelocytic leukemia (APL). The synergistic effect of these compounds
leads to rapid remission in most APL patients, but the molecular basis of this therapeutic
benefit is a matter of debate. RA activates the oncoprotein PML-RARA (the fusion protein
PML-retinoic acid receptor-a), which induces terminal differentiation of leukemia cells.
However, the ability of arsenic trioxide to induce differentiation of leukemia cells is limited.
Meanwhile, both agents are known to trigger degradation of PML-RARA, suggesting that
mechanisms other than differentiation may underlie the synergistic effects mediated by these
drugs. In their study, Nasr and colleagues report that bone marrow from mice injected with
murine APL cells, and treated with RA, showed a marked reduction in the number of LICs in secondary recipients. Further-
more, RA and arsenic trioxide acted synergistically to reduce the number of LICs but did not seem to affect the differentiation
of APL cells, leading the authors to conclude that LIC eradication and not differentiation is in fact the primary basis for APL
remission. They also found that LIC loss was dependent on proteolysis of PML-RARA and was regulated by c-AMP-mediated
phosphorylation, which could explain the synergy in vivo between RA, arsenic trioxide and phosphodiesterase inhibitors. The
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authors discuss that controlling production of PML-RARA in vivo is crucial to prevent LIC self-renewal and hypothesize that
oncoprotein degradation, if linked to CSC self-renewal in other forms of cancer, could be a new anticancer therapeutic
strategy.
R. Nasr et al. (2008). Nat. Med. 14, 1333–1342.
Cancer Stem Cells—A Numbers Game
Not all researchers agree that cancer stem cells (CSCs) are the sole drivers of tumor progression, but most agree that these
tumor-forming cells are a small, distinct subpopulation of the tumor. This assumption comes from limiting dilution transplant
assays where the frequency of a range of human cancer cells that form tumors after transplantation into NOD/SCID mice is
exceedingly low. As a result, many believe that only rare human cancer cells have the potential to proliferate extensively
and that most human cancer cells have little capacity to proliferate or to contribute to disease. Quintana et al. (2008) now reveal
that tumor-forming cells in human melanomas in fact are neither rare nor distinct. Melanoma-initiating cells appeared to be rare
when assayed under conventional conditions in NOD/SCID mice. However, when the authors altered several key assay param-
eters, they could boost the frequency of melanoma-forming cells by several orders of magnitude. These alterations included
using as recipients a NOD/SCID Il2rg/ mouse strain, which is more immunocompromised than the NOD/SCID strain,
enabling more efficient engraftment of human cells. Other alterations included injecting the NOD/SCID Il2rg/ recipient
mice with melanoma cells mixed with matrigel and monitoring tumor formation in the transplanted mice for longer time periods.
Using these modified conditions, the authors injected single unselected melanoma cells and reported that tumors arose in
a striking 27% of the NOD/SCID Il2rg/ recipient mice. They then assessed whether tumor- and non-tumor-forming cells
could be distinguished on the basis of differential expression of cell surface markers. Of the 50 markers surveyed, including
known markers for other CSC populations, the authors found that all melanoma subpopulations injected, irrespective of their
marker profiles, seemed equally capable of regrowing the parental melanoma. They concluded that cells with tumor-forming
potential are common within the tumor and suggest that the frequency and heterogeneity of tumor-forming cell populations in
other types of cancer may be greater than previously thought. Identifying all cancer cells that are able to propagate the disease
remains an important goal, whether they are true stem cells, rare, or neither, but the new findings highlight the challenge in
pinpointing which properties define those cells that actually have the potential to contribute to cancer progression.
E. Quintana et al. (2008). Nature 456, 593–598.
Blood and Bone Intertwined
Hematopoiesis is regulated by both the vascular cells and bone cells of bone marrow, but the
complex interface between these cells has made it difficult to decipher the distinct roles played
by each component. Two recent studies visualize the bone marrow in real time and conclude
that the bone and vascular niches, rather than being distinct, are intimately associated at the
endosteum (the inner surface of bone). Combining confocal microscopy and two-photon video
imaging, Lo Celso et al. (2008) devised a way to follow the movement of hematopoietic stem
and progenitors cells (HSPCs) in real time. Using the Col2.3-GFP mouse, in which osteoblasts
express green fluorescent protein (GFP), the authors labeled blood vessels with quantum dots
and followed the appearance of DiD-labeled HSPCs in live animals. Meanwhile, Xie et al. (2008)
took an ex vivo approach, following GFP-expressing HSPCs in isolated bone sections and
using immunodetection of CD31 and N-cadherin to identify blood vessels and osteoblasts,
respectively. Both groups report that the endosteal surface is highly vascularized, with osteo-
blasts and blood vessels in intimate proximity. To study engraftment, both groups injected
HSPCs into irradiated mice. Lo Celso and colleagues reported that HSPCs were found closer
to the endosteal surface in irradiated compared to control mice and observed that the HSPCs
divided over time on the inner bone surface. Irradiation damages blood vessels, which Lo Celso
et al. visualized by monitoring leakage of dye. In c-Kit-receptor-deficient mice, which allow HSPC engraftment in the absence
of irradiation, and hence with undamaged vessels, these authors showed that HSPCs still settled closer to the endosteal
surface. Xie and colleagues further revealed that because the trabecular region of the bone expressed higher levels of the
chemotactic factor Sdf1 in response to irradiation, more HSPCs homed to this region rather than to compact bone. These
researchers next discovered that HSPCs tended to directly contact preosteoblasts expressing N-cadherin. Lo Celso and
coworkers also demonstrated that the more differentiated the HSPCs, the further away from the endosteum they were
located. They comment that their imaging system cannot decipher whether HSPC engraftment and proliferation requires
direct contact with osteoblasts, and Xie et al. note that not all HSPCs are associated with osteoblasts expressing N-cadherin.
Taken together, these studies show that the endosteum is the preferential site to which HSPCs home and that HSPCs may be
regulated by gradients of factors derived from osteoblasts, blood vessels, and the extracellular matrix.
C. Lo Celso et al. (2008). Nature. Published online December 3, 2008. 10.1038/nature07434.
Y. Xie et al. (2008). Nature. Published online December 3, 2008. 10.1038/nature07639.
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